Customer Issue Driven Model And Structural Reforms Will Reshape Long Term Earnings Quality

Catalysts

About Teijin

Teijin is a diversified Japanese company active in apparel and industrial fibers, healthcare and life solutions, specialty materials, and electronics and energy related materials.

What are the underlying business or industry changes driving this perspective?

• The shift to a customer issue driven business model across Apparel & Industries, Healthcare & Life Solutions, Electronics & Energy and Specialty Materials aims to move Teijin toward higher value solutions rather than commoditized materials. This is intended to support more resilient revenue growth and a higher adjusted operating income base.
• Integration of Teijin Frontier with Asahi Kasei Advance into TA Frontier combines polyester and nylon platforms, wider processing technologies and an expanded construction materials customer base. This is expected to broaden solution offerings and support higher sales and potentially stronger margins in Apparel & Industries.
• Expansion of home healthcare from outpatient support into visiting type home healthcare and adjacent residential care style services, supported by M&A and alliances, targets rising healthcare needs and can deepen recurring CPAP and ventilation device usage, with the aim of supporting revenue growth and steadier earnings in Healthcare & Life Solutions.
• The creation of Electronics & Energy by combining resins, battery materials and semiconductor solutions around overlapping customers positions Teijin to supply materials and solutions linked to electrification and electronics demand. Management expects this to support stable adjusted operating income and return on invested capital.
• Structural reforms in Specialty Materials, including cost structure reviews, lower depreciation after impairments and the focus on aerospace, personal protection, defense and infrastructure applications where aramid and carbon fibers are highly valued, are intended to lift this segment from losses to positive adjusted operating income and ROIC above the cost of capital by fiscal 2028.
• Group wide focus on freeing up cash through asset sales, reducing interest bearing debt and reallocating capital into higher return Apparel & Industries and Healthcare & Life Solutions businesses is designed to support the targeted rise in adjusted operating income to ¥60b and ROE to 8%, while keeping the balance sheet metrics such as the adjusted D/E ratio on an improving path.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Teijin compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Teijin's revenue will grow by 4.2% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from -4.9% today to 4.0% in 3 years time.
• The bullish analysts expect earnings to reach ¥38.3 billion (and earnings per share of ¥198.65) by about September 2029, up from -¥42.2 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as ¥17.9 billion.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 11.4x on those 2029 earnings, up from -8.1x today. This future PE is lower than the current PE for the JP Chemicals industry at 12.7x.
• The bullish analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.63%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Teijin is still working through the impact of very large impairment losses in aramid, Healthcare and carbon fibers, which kept nonrecurring items almost flat at a loss of JPY 93.8b year-on-year and resulted in Profit Attributable to Owners of Parent being a loss of JPY 88b. If future reviews of assets in these areas lead to further write downs, this could weigh on net profit and ROE for longer than expected.
• The Materials and Specialty Materials related businesses are already affected by commoditization and a deterioration in the sales mix for aramid and carbon fibers, which contributed to adjusted operating income in Materials falling to JPY 100m and Specialty Materials recording a loss of JPY 9b. If pricing pressure on these products persists, it could limit revenue quality and keep segment margins under strain.
• Teijin is relying heavily on restructuring and portfolio moves, such as the sale of the North American Composites business, the divestiture of Aramid Paper and continued workforce reductions. If these actions do not translate into the planned JPY 20b uplift from structural reforms, the company may find it difficult to reach the targeted JPY 60b adjusted operating income and 8% ROE, which would affect earnings and capital efficiency.
• The Pharmaceuticals business is being streamlined, with explicit reference to lower volumes and NHI drug price revisions expected to hurt earnings by about JPY 7b. If further pricing revisions or additional exits from conventional pharmaceuticals are required, this could drag on Healthcare & Life Solutions revenue and keep adjusted operating income below the JPY 13.4b level reported for fiscal 2025.
• The new customer issue driven model requires breaking down long established business silos, unifying IT systems into a one data platform and ramping up AI usage. If Teijin faces delays or execution problems in these group wide changes, the expected efficiency gains and higher quality earnings base may not fully appear, which would affect adjusted operating income growth and limit improvement in net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Teijin is ¥1860.0, which represents up to two standard deviations above the consensus price target of ¥1582.0. This valuation is based on what can be assumed as the expectations of Teijin's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ¥1860.0, and the most bearish reporting a price target of just ¥1250.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be ¥965.0 billion, earnings will come to ¥38.3 billion, and it would be trading on a PE ratio of 11.4x, assuming you use a discount rate of 6.6%.
• Given the current share price of ¥1766.5, the analyst price target of ¥1860.0 is 5.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.